Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain

A Phase IIa Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 After 3 Weeks of Treatment in Patients With Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)

The primary aim of this study is to investigate if AZD1386 is efficacious as an analgesic in patients with peripheral neuropathic pain. This will be done by comparing the effect of AZD1386 to placebo ("inactive substance") on pain.

Inclusion Criteria:

• Patients with painful symptoms due to neuropathic pain
• Provision of signed informed consent
• Non pregnant females

Exclusion Criteria:

• Other pain conditions that may confound assessment of neuropathic pain, as judged by the investigator
• History, and/or presence of somatic disease, which may interfere with the objectives of the study as judged by the investigator